Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05831891 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Non-clear Renal Cell Carcinoma

Interventions

DRUG: Fruquintinib combined with Serplulimab

Sponsor

RenJi Hospital

Collaborators

[object Object]
[object Object]
[object Object]